title: [Influence of hemantane in injectable dosage form on levodopa-induced dyskinesia in rats with model parkinsonian syndrome].
abstract: Levodopa-induced heavy dyskinesia was modeled in rats with severe hemiparkinsonian syndrome induced by injection of 6-hydroxydopamine in the left medial forebrain bundle. It is established that the antidyskinetic effect of the injectable dosage form of a new antiparkinsonian drug hemantane (5 mg/kg) after a single intravenous administration is weaker than that of the most effective in clinical practice antidyskinetic drug amantadine (20 mg/kg). However, after five days of treatment, the effect of hemantane injections exceeded that of amantadine.
authors.forename: I G
authors.initials: IG
authors.lastname: Kapitsa
authors.forename: E A
authors.initials: EA
authors.lastname: Ivanova
authors.forename: I I
authors.initials: II
authors.lastname: Kokshenev
authors.forename: A V
authors.initials: AV
authors.lastname: Nepoklonov
authors.forename: E A
authors.initials: EA
authors.lastname: Val'dman
authors.forename: T A
authors.initials: TA
authors.lastname: Voronina
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives* / Q000494:pharmacology; D018663:Adrenergic Agents / Q000009:adverse effects* / Q000494:pharmacology; D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000494:pharmacology; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000503:physiopathology*; D007980:Levodopa / Q000009:adverse effects* / Q000494:pharmacology; D008297:Male; D016627:Oxidopamine / Q000009:adverse effects* / Q000494:pharmacology; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology*; D051381:Rats
chemical_list: D018663:Adrenergic Agents; D000978:Antiparkinson Agents; C526127:hemantane; D007980:Levodopa; D016627:Oxidopamine; D000218:Adamantane